Title(s): 
SWOG 1207. Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
Investigator(s): Esther Rehmus, MD
Contact Information: McDowell Cancer Research at 330.344.6348 

Title(s): 
NSABP B-51/RTOG 1304. A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Investigator(s): Andrew Fenton, MD
Contact Information: McDowell Cancer Research at 330.344.6348 

Title(s):
CTSU E2112. A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer
Investigator(s): Esther Rehmus, MD
Contact Information: McDowell Cancer Research at 330.344.6348 

Title(s):
NSABP B-55/BIG 6-13. A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Investigator(s): Andrew Fenton, MD
Contact Information: McDowell Cancer Research at 330.344.6348

Title(s):
CTSU A011202. A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Investigator(s): Esther Rehmus, MD
Contact Information: McDowell Cancer Research at 330.344.6348 

Title(s):
CTSU EA1131. A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Investigator(s): Esther Rehmus, MD
Contact Information: McDowell Cancer Research at 330.344.6348

Title(s):
NRG-BR003. A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Investigator(s): Esther Rehmus, MD
Contact Information: McDowell Cancer Research at 330.344.6348

Title(s):
NRG-BR002. A Phase IIR/III Trial of Standard of Care with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Investigator(s): Mitchell Fromm, MD
Contact Information: McDowell Cancer Research at 330.344.6348

Title(s):
CTSU A011401. Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Investigator(s): Esther Rehmus, MD
Contact Information: McDowell Cancer Research at 330.344.6348

Title(s):
16019. A Multicenter Randomized Controlled Trial of Routine Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients
Investigator(s): Andrew Fenton, MD
Contact Information: McDowell Cancer Research at 330.344.6348

Title(s):
CTSU A011502. A randomized phase III double blinded placebo-controlled trial of aspirin as adjuvant therapy for node-positive, HER2 negative breast cancer: the ABC trial
Investigator(s): Esther Rehmus, MD
Contact Information: McDowell Cancer Research at 330.344.6348

Title(s):
SWOG 1416. Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
Investigator(s): Esther Rehmus, MD
Contact Information: McDowell Cancer Research at 330.344.6348

Title(s):
17013. Mammaprint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry (FLEX Registry)
Investigator(s): Esther Rehmus, MD
Contact Information: McDowell Cancer Research at 330.344.6348